Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia

Acta Haematologica

Volumn 98, Issue 4, 1997, Pages 204-210

  Mittelman, Moshe ^a   Zeidman, Aliza ^a   Fradin, Zinaida ^a   Magazanik, Avraham ^a   Lewinski, Uri H ^a   Cohen, Amos ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Anemia; Erythropoietin; Multiple myeloma; Multiple myeloma associated anemia; Recombinant human erythropoietin

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; HEMOGLOBIN DETERMINATION; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; QUALITY OF LIFE; SKIN IRRITATION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0030776896     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000203625     Document Type: Article

References (42)

1. Kyle RA: Multiple myeloma: Review of 869 cases. Mayo Clin Proc 1975:50:29-37.
2. Duric BGM, Salmon SE: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975;36:842-852.
3. Beguin Y, Yerna M, Loo M, Weber M, Fillet G: Erythropoiesis in multiple myeloma: Defective red cell production due to inappropriate erythropoietin production. Br J Haematol 1992;82: 648-653.
4. Miller CB, Jones RJ, Plantadosi S, Abeloff MD, Spivak JL: Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689-1692.
5. Ludwig H, Fritz E, Kotzmann H, Hocker P, Gisslinger H, Bamas U: Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990;322:1693-1699.
6. Mittelman M: Anemia of cancer: Pathogenesis and treatment with recombinant human erythropoietin - an improved quality of life. Isr J Med Sci 1996;32:1201-1206.
7. Salmon SE, Cassady JR: Plasma cell neoplasms; in DeVita VT Jr, Heilman S, Rosenberg SA (eds): Cancer - Principles and Practice of Oncology, ed 3. Philadelphia, Lippincott, 1989, pp 1853-1895.
8. Barlcgie B, Smith L, Alexanian R: Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984:310:1353-1356.
9. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207-214.
10. Spivak JL, Pham TH, Isaacs MA, Hankins WD: Erythropoietin is both a mitogen and a survival factor. Blood 1991;77:1228-1233.
11. Mittelman M: Recombinant erythropoietin in myelodysplastic syndromes: Whom to treat and how? More questions than answers. Acta Haematol 1993;90:53-57.
12. Mittelman M, Lessin LS: Clinical application of recombinant erythropoietin in myelodysplasia. Hematol Oncol Clin North Am 1994;8: 993-1009.
13. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW: Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989;321:158-163.
14. Henry DH, Beall GN, Benson CA, Carey J, Cone LA, Eron LJ, Fiala M, Fischl MA, Gabin SJ, Gottlieb MS, Galpin JE, Groopman JE, Hooton TM, Jemsck JG, Levine RL, Miles SA, Rinehart JJ, Rios A, Robbins WJ, Ruckdeschel JC, Smith JA, Spruance SL, Starrett B, Toney J, Zalusky R, Abels RI, Bryant EC, Larholt KM, Sampson AR, Rudnick SA: Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy: Overview of four clinical studies. Ann Intern Med 1992;117:739-748.
15. Spivak JL: Recombinant erythropoietin and the anemia of cancer. Blood 1994;84:997-1004.
16. Barlogie B, Beck T: Recombinant human erythropoietin and the anemia of multiple myeloma. Stem Cells 1993;11:88-94.
17. Cline MJ, Berlin NI: Studies of the anemia of multiple myeloma. Am J Med 1962;33:510-525.
18. Kopp WL, MacKinney AA Jr, Wasson G: Blood volume and hematocrit value in macro-globulincmia and myeloma. Arch Intern Med 1969;123:394-396.
19. Singh A, Eckardt KU, Zimmermann A, Gotz KH, Hamann M, Ratcliffe PJ, Kurtz A, Reinhart WH: Increased plasma viscosity as a reason for inappropriate erythropoietin formation. J Clin Invest 1993;91:251-256.
20. Lee GR: The anemia of chronic disease. Semin Hematol 1983;20:61-80.
21. Faquin WC, Schneider TJ, Goldberg MA: Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992;79:1987-1994.
22. Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J, Liautard J, Merlin M, Clement C, Morel-Foumicr B, Lu ZY, Man-noni P, Sany J, Bataille R: Murine anti-inter-leukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991; 78:1198-1204.
23. Ariad S, Clifford D, Pcnfold G, Macphail AP, Bezwoda WR: Erythropoietin response in anemia patients with multiple myeloma and other lymphoid malignancies infiltrating the bone marrow. Europ J Haematol 1992;49:59-62.
24. Aoki I, Nishijima K, Homori M, Nakahara K. Higashi K, Ishikawa K: Responsiveness of bone marrow crythroid progenitors (CFU-E and BFU-E) to recombinant human erythropoietin in vitro in multiple myeloma. Br J Haematol 1992;81:463-469.
25. Ludwig H, Leitgeb C, Fritz E, Krainer M, Kuhrcr I, Komek G, Sagaster P, Wcibmann A: Erythropoietin treatment of chronic anaemia of cancer. Eur J Cancer 1993;29A(suppl 2):S8-S12.
26. Peschcrstorfer M, Schmoranzer F, Vcscly M, Fortelny A, Baumgartner G: Erythropoietin beim multiplen Myelom (erythropoietin in multiple myeloma). Dtsch Med Wschr 1990; 115:1096-1099.
27. Molica S: Erythropoietin treatment of anaemia associated with lymphoproliferative disorders. Eur J Cancer 1993;29A: 1499-1500.
28. Bessho M, Hirashima K, Tsuchiya J: Improvement of anemia in patients with multiple myeloma by recombinant erythropoietin: A multicenter study. Exp Hematol 1994; 22:705.
29. Garton JP, Gertz MA, Witzig TE, Greipp PR, Lust JA, Schrocdcr G, Kyle RA: Epoetin-a for the treatment of the anemia of multiple myeloma - a prospective, randomized, placebo-controlled, double-blind trial. Arch Intern Med 1995;155:2069-2074.
30. Silvestris F, Romito A, Fanelli P, Vacca A, Dammacco F: Long-term therapy with recombinant human erythropoietin (rHuEPO) in progressing multiple myeloma. Ann Hematol 1995;70:313-318.
31. Adam Z, Krahulova M, Spelda S, Vorlicek N, Hejlova N, Hejlova N, Hajek R, Tomiska M: Therapy of anemia in patients with multiple myeloma. Acta Med Austriaca 1995;22:59-64.
32. Cazzola M, Messingcr D. Battistel V, Bron D, Cimino R, Enller-Ziegler L, Essers U, Greil R. Grossi A, Jager G: Recombinant human erythropoietin in the anemia associated with multiple myeloma or non- Hodgkin’s lymphoma: Dose finding and identification of predictors of response. Blood 1995;86:4446-4453.
33. Dammacco E, Caatoldi G, Grassi B, Berna-sooni C. Pcrona G: The effectiveness and toler-ability of recombinant human erythropoietin (epoctin-a) in patients with multiple myeloma refractory to chemotherapy. Eur J Cancer 1995;31A(suppl 5):S51.
34. Osterborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, Jager G, Najman A, Peest D:. Recombinant human erythropoietin in transfusion-dependent anemia patients with multiple myeloma and non-Hodgkin’s lymphoma - a randomized multicenter study. Blood 1996;87:2675-2682.
35. Rogers S. Russell NH, Morgan AG: Effect of erythropoietin in patients with myeloma. Br Med J 1990;301:667.
36. Ruedin P, Pecherc-Bcrtschi A, Chapuis B, Ben-cdct P, Leski M: Safety and efficacy of recombinant human erythropoietin treatment of anaemia associated with multiple myeloma in hacmodialysed patients. Nephrol Dial Transplant 1993;8:315-318.
37. Mittelman M, Floru S, Djaldetti M: Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Blood 1992:80:841.
38. Ludwig H, Fritz E, Leitgeb C, Pechcrstorfer M, Samonigg H, Schuster J: Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994;84:1056-1063.
39. Dessypris E, Gräber SE, Krantz SB, Stone WJ: Effects of recombinant erythropoietin on the concentration and cycling status of human marrow hematopoietic progenitor cells in vivo. Blood 1988;72:2060-2062.
40. Okuno Y, Takahashi T, Suzuki A, Ichiba S, Nakamura K. Hitomi K, Sasaki R, Imura H: Expression of the erythropoietin receptor on a human myeloma cell line. Biochem Biophys Res Commun 1990:170:1128-1134.
41. Adamson JW: The relationship of erythropoietin and iron metabolism to red cell production in humans. Semin Oncol 1994;21(suppl 3):9-15.
42. Mittelman M, Gardyn J, Carmel M, Malovani H, Barak Y, Nir U: Analysis of the erythropoietin receptor gene in patients with myeloproliferative and myelodysplastic syndromes. Leuk Res 1996;20:459-466.